TELA Bio's New CEO Faces a Revenue Miss and a Cash Crunch
A botched PRS pilot, anti-competitive bundling, and a guidance withdrawal prompt a cost-cutting overhaul under new leadership.
TELA · Earnings Call · 2026-08-10
A New Hand on the Helm
TELA Bio started its Q2 2026 earnings call with a surprising change at the top: the company named Heather Goetz as the new CEO, replacing founder Antony Koblish. The transition comes at a critical juncture. Revenue for the quarter fell to $19.3 million, a 4% decline year-over-year, and management pulled its full-year guidance. “the results of the business this quarter do not reflect the quality and potential of the portfolio” — Louisa Smith, Unknown (likely investor relations or communications) · 2026-08-10 Goetz said, attributing the shortfall to slower-than-expected sales rep productivity, a misstep in the PRS pilot, and ongoing anti-competitive bundling.The PRS Misstep and the Bundling Battle
The decline was concentrated in OviTex PRS, where revenue dropped 23% on lower unit volume. Management admits that a pilot program to dedicate reps to PRS backfired, creating confusion across the sales organization. “We acted fast, and stopped the pilot” — Jeffrey Blizard, President · 2026-08-10 said Jeff Blizard, President. The company is also fighting what it calls competitive dynamics of bundling—a practice it alleges is used by larger rivals like Becton Dickinson to lock TELA out of hospitals. The company points to a recurrence rate of 2.6% in its BRAVO study, arguing its product's clinical outcomes should win on merit.Cost Cuts and Cash Preservation
With the business forecast now uncertain, CFO Roberto Cuca announced a plan to reduce costs.he said, adding that the company will "meaningfully reduce the overall cost structure." The company ended Q2 with $30.4 million in cash, but the burn rate remains high. The company's effective net cash stands at -$16M, reflecting the debt taken on to fund operations. Management says it aims to extend its cash runway and treat further fundraising as a "last resort." The new team is also wrestling with a longer than expected rep ramp. Jim Hagen, SVP of commercial operations, admitted in the call: “We are definitely seeing it longer... we are really looking at that 9- to 12-month ramp for reps to get up to a really strong productivity level.” — Jim Hagen, Unknown (likely senior management or commercial leader) · 2026-08-10 That contrasts sharply with the optimistic outlook just a few months earlier, when the company believed “That 40% of new reps will be through their 6 month bed in period” — Antony Koblish, Chief Executive Officer · 2026-05-12. Back in March, management also maintained that “the most recent cohorts of sales reps hit breakeven just under six months” — Roberto E. Cuca, Chief Commercial Officer · 2026-03-24. For a microcap with a market capitalization of just $42 million and annualized revenue around $77 million, the loss of guidance and pledge to cut costs suggests a company in survival mode. The real test will be whether the new CEO can stabilize the commercial organization, win the bundling fight, and scale the PRS portfolio without running out of cash.we believe it is prudent for us to withdraw our prior full year revenue guidance